Vascular Biogenics Ltd

NASDAQ:VBLT  
2.15
+0.01 (+0.47%)
Products, Regulatory

VBL Therapeutics Provides Update On Phase 3 Study Of VB-111 In Ovarian Cancer

Published: 06/15/2021 11:22 GMT
Vascular Biogenics Ltd (VBLT) - Vbl Therapeutics Provides Update on Oval, a Phase 3 Registration Enabling Study of Vb-111 in Ovarian Cancer.
Vbl Therapeutics - Was Notified by FDA That Clearance of New Vb-111 Batches for Use in U.S. is Currently Pending Completion of Review by Cmc Group.
Vbl Therapeutics - Until New Batches Are Cleared, Company Anticipates a Temporary Shortage of Study Drug Supply for U.S.vbl Therapeutics - Accordingly, Recruitment of New Patients in U.S. Will Be Temporarily Paused.
Vbl Therapeutics - Treatment Will Continue As Usual for All U.S. Patients Currently Enrolled.